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Introduction: Somnambulism or sleepwalking is a disorder of arousal from non-rapid eye movement sleep. The
prevalence of sleep-related eating disorder has been found to be approximately between 1% and 5% among
adults. Many cases of medication-related somnambulism and sleep-related eating disorder-like behavior have been
reported in the literature. Quetiapine, an atypical antipsychotic medication, has been associated with
somnambulism but has not yet been reported to be associated with sleep-related eating disorder.
Case presentation: Case 1 is a 51-year-old obese African American male veteran with a body mass index of
34.11kg/m2 and severe sleep apnea who has taken 150mg of quetiapine at bedtime for more than one year for
depression. He developed sleepwalking three to four nights per week which resolved after stopping quetiapine
while being compliant with bi-level positive pressure ventilation therapy. At one year follow-up, his body mass
index was 32.57kg/m2.
Case 2 is a 50-year-old African American female veteran with a body mass index of 30.5kg/m2 and mild sleep
apnea who has taken 200mg of quetiapine daily for more than one year for depression. She was witnessed to
sleepwalk three nights per week which resolved after discontinuing quetiapine while being treated with continuous
positive airway pressure. At three months follow-up, her body mass index was 29.1kg/m2.
Conclusion: These cases illustrate that quetiapine may precipitate complex motor behavior including sleep-related
eating disorder and somnambulism in susceptible patients. Atypical antipsychotics are commonly used in
psychiatric and primary care practice, which means the population at risk of developing parasomnia may often go
unrecognized. It is important to recognize this potential adverse effect of quetiapine and, to prevent injury and
worsening obesity, discuss this with the patients who are prescribed these medications.
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Sleep-related eating disorder (SRED) represents recur-
rent episodes of involuntary eating and drinking during
the main sleep period with one or more features of con-
sumption of peculiar foods, insomnia, sleep-related in-
jury, dangerous behaviors performed while in pursuit of
food, morning anorexia and adverse health conse-
quences from recurrent binge eating of high caloric food
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reproduction in any medium, provided the orarousal from non-rapid eye movement (NREM) sleep
which often co-exists with SRED [3,6].
Many cases of medication-related somnambulism and
SRED-like behavior have been reported in the literature.
Zolpidem is one of the most commonly reported medi-
cations associated with these conditions. Quetiapine
(Seroquel), a piperazinyl-dibenzothiazepine analog of
clozapine, is an atypical antipsychotic medication fre-
quently used for the treatment of schizophrenia, bipolar
disorder and major depressive disorder as an adjunct to
an antidepressant. It has been infrequently reported to
be associated with sleepwalking [7] and in one case, it
has actually been used to treat sleepwalking [8]. How-
ever, to the best of our knowledge, quetiapine has not
yet been reported to be associated with the development
of SRED.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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were induced or aggravated by quetiapine because in
both cases the condition resolved completely after dis-
continuation of the medication. In addition, both




A 51-year-old African American male veteran presented
to our sleep clinic, accompanied by his wife, with com-
plaints of daytime sleepiness, sleepwalking and eating
during sleep for more than a year. He reportedly walks
and eats uncooked food from the refrigerator and mis-
places things during sleep three to four nights per week.
His wife saw him walking around inside the house
dressed up in his best outfit in the middle of the night
carrying the car key. The patient could not remember
any of these events after awakening.
His past medical history included depression, hyper-
tension and mood disorder. There was no previous his-
tory of seizure, childhood or family history of
parasomnia or alcohol abuse. His medications included
bupropion, quetiapine, lisinopril, hydrochlorothiazide
and loratadine. He was diagnosed with major depression
about eight years ago and received bupropion 150mg
two times a day for treatment. He underwent a major fi-
nancial crisis with job loss and had to move to his
mother’s house. His symptoms of depression were not
improving and quetiapine was added about six years ago
to help improve his depression. The dose of quetiapine
was gradually titrated up to 150mg at bedtime by his
psychiatrist. It is not clear when his SRED first started
because the patient used to live alone until one year ago
when he got married. His physical examination was un-
remarkable except for an elevated BMI of 34.11kg/m2
and poorly controlled hypertension. An overnight poly-
somnography was performed which revealed severe
sleep apnea (apnea hypopnea index (AHI) of 86/hour
with an arousal index of 156/hour). No parasomnia or
periodic limb movements were noted during polysomno-
graphy. During the overnight titration study, his sleep
apnea responded well to bi-level positive pressure venti-
lation (BiPAP) with optimal resolution of his apnea and
hypopneas and there were not many treatment emergent
central apneas. He was sent home on nightly BiPAP
therapy and was scheduled for a follow-up in three
months.
On his follow-up visit, he reported good compliance
with his BiPAP (99% compliance for >4 hours per night
for >4 nights per week, verified by the memory card in-
stalled in the BiPAP machine). His daytime sleepiness
improved significantly but his wife complained of
increased frequency of sleepwalking and eating duringsleep almost every other night after starting him on
BiPAP. Because quetiapine has been known to be asso-
ciated with sleepwalking, he was advised to discontinue
it. He returned for a follow-up in three months and, sur-
prisingly, he did not have any further incidents of either
SRED or sleepwalking. There was no change in any
other medication except discontinuation of his quetia-
pine during this interval. He lost 0.91kg (2lb) during this
three months follow-up. He was also followed up after
one year of stopping quetiapine and he reported restful
sleep without any further event of sleepwalking or eating
during sleep. His BMI was 32.57kg/m2 and he had lost
4.08kg (9lb). His serum quetiapine level had never been
measured.
Case 2
A 50-year-old African American obese (BMI=30.5kg/m2)
female veteran with a history of hypertension, asthma,
major depressive disorder, migraine and obstructive sleep
apnea presented to the clinic for follow-up. Her medica-
tions included verapamil, lisinopril, hydrochlorothiazide,
bupropion, venlafaxine, topiramate and quetiapine.
She complained of walking in her sleep and eating
from the refrigerator while she was asleep. These inci-
dents were observed and reported by her niece and
brother who lived in the same house. She was seen to
walk and sit at the kitchen table with her eyes closed, eat
cereal and go back to bed. They also mentioned that she
started her electric coffee pot, putting water in it and
went to bed at 3 a.m. She was having these episodes two
to three nights per week. She was also diagnosed with
obstructive sleep apnea after a baseline sleep study a few
years back which showed obstructive sleep apnea
(AHI = 10/hour) that was worse during REM sleep
(REM AHI = 58/hour). She was prescribed continuous
positive airway pressure (CPAP) at 8cm after adequate
titration study but she was having trouble keeping her
mask in place due to her sleepwalking episodes during
which she removed the mask.
Over the past four years she was being treated with
quetiapine for depression. This medication was added as
an adjunct therapy when other medications did not con-
trol her symptoms adequately. Her quetiapine dose was
increased to 200mg daily about a year ago for increasing
depression from work-related stress. She could not give a
correct history when the sleepwalking exactly started but
it has been witnessed for six to eight months. As her
medication list shows, she was already on topiramate for
her migraine headache which was continued after stop-
ping quetiapine. Although topiramate has been shown to
be effective in SRED in a small trial [2], it did not help in
her SRED symptoms. We tapered and eventually stopped
her quetiapine. After three months, she reported during
her follow up visit that she no longer had episodes of
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other medication except discontinuation of her quetia-
pine during this interval. She could now use her CPAP
every night and felt rested after her sleep. Her BMI was
29.1kg/m2 and she had lost 3.18kg (7lb).
Discussion
SRED is characterized by recurrent episodes of partial
arousals with involuntary eating during the main sleep-
ing period, usually within the first three hours of sleep.
A strong association between somnambulism and SRED
has been reported. Somnambulism has been primarily
linked to NREM sleep instability, particularly an abnor-
mality in regulation of slow wave sleep (SWS). It is com-
monly precipitated by other factors including sleep
deprivation, presence of other primary sleep disorders
(sleep apnea, periodic limb movement disorder) as well
as medications that raise the threshold for arousals [3].
Our patients had a few important predisposing factors
for parasomnia including increased work-related stress,
depression and severe sleep apnea with high arousal
index. If a patient with parasomnia has any other con-
comitant primary sleep disorder, the treatment is initially
directed towards that aspect which often resolves the
parasomnia. Our first patient had severe sleep apnea that
was treated adequately, but he continued to have sleep-
walking and SRED despite good compliance with treat-
ment probably because his SWS had increased after
using BiPAP. Our second patient was not able to be
compliant with the CPAP initially until she stopped tak-
ing quetiapine.
Sleepwalking and SRED have been commonly reported














Figure 1 Potential mechanism of quetiapine-induced SRED and somn
VLPO: ventrolateral preoptic nucleus.However, one case report has proposed quetiapine as a
potential treatment of somnambulism because it
decreases brain delta activity [8]. The somnambulism
phenomenon from quetiapine may be explained by the
serotonin hypothesis of parasomnia [11]. Quetiapine is
found to block 5-hydroxytryptamine-2A (5HT-2A) and
dopamine receptors subtype 2 (D2) increasing cortical
dopamine release by 5HT-1A agonism [12]. The seroto-
nergic neurons of the dorsal raphe nucleus (DRN) in the
brain stem constitute an integral component for gener-
ation of SWS. Among a variety of subtypes of serotoner-
gic receptors, 5HT-2A receptors in the DRN are known
to regulate frequency and amplitude of SWS [13]. These
neurons projecting into the ventrolateral preoptic area
help maintain and increase the SWS. These serotonergic
neurons are also thought to modulate the motor system
by dampening the sensory input and attenuating cortical
activation, which helps maintain the hypotonia of the
antigravity muscles during SWS. Normally, maintenance
of SWS is well coordinated with motor inhibition so that
motor activity does not happen without an arousal. A
blockade of serotonergic input can withdraw this motor
inhibition, enabling the person to walk and perform
other motor activities. Quetiapine has been known to
alter central serotonin activity by blocking the 5-HT ser-
otonergic receptor which may, in turn, dissociate these
two components (state of sleep and muscle hypotonia)
[12], leading to sleepwalking without a complete arousal.
From the literature support described above, we
propose a potential mechanism of quetiapine-induced
SRED and somnambulism phenomenon explained in
Figure 1. Sleepwalking aggravated by quetiapine may be














ambulism. SRED: sleep-related eating disorder; SWS: slow wave sleep;
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again related to its effect on another serotonin receptor:
5HT-2C. The serotonin receptor 5HT-2C in the hypo-
thalamus regulates mood, anxiety, feeding, and repro-
ductive behavior [14]. Antagonism of the serotonin
receptor 5HT-2C by antipsychotic drugs, including que-
tiapine, olanzapine and clozapine, increases appetite
leading to increased food intake and weight gain [15].
Patients who are on these antipsychotic medications and
gaining weight were also found to have elevated leptin
levels [16]. Because quetiapine blocks 5HT-2C, it may
cause leptin resistance at the level of the hypothalamus,
contributing to increased food intake and obesity
(Figure 1). Often, an obese body shape is not even per-
ceived to be a problem or stressful, as assessed by the
perceived stress scale [17].
Conclusion
Quetiapine may increase the potential of SRED-like
complex motor behavior in susceptible patients. SRED is
more common than is generally recognized and the
prevalence of SRED is high in the adult psychiatric
population [18]. Atypical antipsychotics are commonly
used in psychiatric and primary care practice, which puts
the population at risk of getting parasomnia that may
often go unrecognized. It is important to discuss this po-
tential adverse effect with patients who are on these
medications to prevent injuries and worsening obesity
with its complications [19]. Further research is necessary
to explore the exact mechanisms of how quetiapine can
cause and/or aggravate SRED.
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